Rx Products (September 2019)

Pharmacy Times, September 2019 Pain Management, Volume 85, Issue 9

Rx Products for September 2019

GUARDED LUER CONNECTORS

MANUFACTURED BY: Medi-Dose/EPS

INDICATION: The Guarded Luer Connectors are designed to facilitate the mixing or transfer of fluids between syringes and connecting various intravenous sets. Available in Female to Female Luer Lock or Female to Male Luer Lock configurations, the connectors are brightly colored for quick identification, and they are individually packaged to facilitate aseptic technique. The connecters are also designed with large finger grips to provide secure manipulation and protect against contamination.

FOR MORE INFORMATION: medidose.com

TURALIO (PEXIDARTINIB)MANUFACTURED BY: Daiichi Sankyo

INDICATION: The FDA has approved Turalio, the first, and currently only, treatment for adult patients with a symptomatic tenosynovial giant cell tumor associated with functional limitations or severe morbidity and not responsive to improvement with surgery. Of the 120 patients in the clinical trial, 38% receiving Turalio had at least a 30% reduction in tumor length at 25 weeks; 56% saw at least a 50% reduction in tumor volume. Common adverse effects include changes in blood liver tests and hair color, increased cholesterol level in the blood, and tiredness.

DOSAGE FORM: Capsules

FOR MORE INFORMATION: turalio.com

SYMJEPIMANUFACTURED BY: Sandoz Inc

INDICATION: Novartis’ Sandoz division is introducing Symjepi (epinephrine) in the US market. The 0.3-mg injections are indicated for the emergency treatment of anaphylactic allergic reactions. The injection works by reducing swelling in the airway and preventing fatal reactions to drugs, food, insect bites and stings, and other substances that induce anaphylaxis. The German drug company is expanding to bring an affordable option of a pre-filled, single-dose auto-injector to US patients.

DOSAGE FORM: Auto-injector device

FOR MORE INFORMATION: sandoz.com

XPOVIO (SELINEXOR)MANUFACTURED BY: Karyopharm Therapeutics Inc

INDICATION: The FDA has approved Xpovio tablets to treat multiple myeloma when taken alongside dexamethasone. Xpovio is a first- in-class, oral selective inhibitor of nuclear export compound. It is indicated for adults with multiple myeloma that has relapsed or who did not respond to previous treatment and have received at least 4 prior therapies. Common adverse effects include anemia, constipation, shortness of breath, and tiredness.

DOSAGE FORM: Tablets

FOR MORE INFORMATION: karyopharm.com